Guerra Daniel R., Gibson C. Michael
TIMI Data Coordinating Center and Angiographic Core Laboratory, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA.
Curr Treat Options Cardiovasc Med. 2004 Feb;6(1):69-77. doi: 10.1007/s11936-004-0016-5.
In the treatment of acute myocardial infarction (AMI), the length of time from symptom onset to revascularization is a crucial determinant of clinical outcomes such as mortality and reinfarction. Direct, or primary, percutaneous transluminal coronary angioplasty (PTCA) produces higher rates of infarct-related artery patency and improved clinical outcomes compared to thrombolytic therapy. However, primary PTCA is associated with an increased time interval from hospital arrival to revascularization, the so-called door-to-balloon time. Numerous data support the theory that increased door-to-balloon time reduces the benefits of primary PTCA in the treatment of AMI. Therefore, institutions that offer PTCA must strive to decrease door-to-balloon delays through the use of established treatment protocols and frequent assessment of performance.
在急性心肌梗死（AMI）的治疗中，从症状发作到血管再通的时间长度是诸如死亡率和再梗死等临床结局的关键决定因素。与溶栓治疗相比，直接或初次经皮腔内冠状动脉成形术（PTCA）能使梗死相关动脉通畅率更高，临床结局得到改善。然而，初次PTCA与从入院到血管再通的时间间隔增加有关，即所谓的门球时间。大量数据支持这样的理论，即门球时间增加会降低初次PTCA治疗AMI的益处。因此，提供PTCA治疗的机构必须通过使用既定的治疗方案和频繁评估性能来努力减少门球延迟。
